Pulmonary Hypertension News

June 20, 2022June 20, 2022

Sotatercept Could Be Effective PAH Treatment, Rodent Models Suggest

Treatment with an analog of sotatercept, Acceleron Pharma’s experimental therapy, eased disease-associated inflammation and changes in blood vessel architecture in multiple rodent models of pulmonary arterial hypertension (PAH), a study reported. ... Read more

June 17, 2022June 17, 2022

KER-012 Again Shows Potential as PAH Treatment in Preclinical Studies

Pulmonary Hypertension News

A research form of Keros Therapeutics’ investigational therapy KER-012, called RKER-012, reduced lung inflammation and scarring (fibrosis) in a rat model of pulmonary arterial hypertension (PAH). The therapy also prevented an ... Read more

June 15, 2022June 15, 2022

Inhaled Seralutinib Shows Promise in 2 PAH Animal Models

Pulmonary Hypertension News

Seralutinib (GB002), an investigational inhaled treatment for pulmonary arterial hypertension (PAH), effectively treated severe disease in two animal models, a study demonstrated. Further, when compared directly, inhaled seralutinib showed greater efficacy ... Read more

June 13, 2022June 13, 2022

Cannabidiol Found to Ease Oxidative Stress, Inflammation in Rat Model

Pulmonary Hypertension News

Treatment with cannabidiol (CBD) reduced inflammation and lessened damaging oxidative stress in a rat model of pulmonary hypertension (PH), a new study reports. “The promising results of our research may ... Read more

June 10, 2022June 10, 2022

Low Sodium, Need for Vasopressors Among PAH Mortality Risk Factors

Pulmonary Hypertension News

Despite recent advances in care, mortality while in the intensive care unit (ICU) and up to one year thereafter remains high among people with pulmonary arterial hypertension (PAH), a new ... Read more

June 8, 2022June 8, 2022

Dysfunction of Heart Left Ventricle Linked to Worse Prognosis in IPAH

Pulmonary Hypertension News

High scores on a measure known as H2FPEF — which reflect an increased probability of dysfunction of the left ventricle (LV) of the heart — were associated with signs of ... Read more

June 6, 2022June 6, 2022

Sacubitril-Valsartan Eases PH in Some Heart Failure Patients

Pulmonary Hypertension News

Sacubitril-valsartan — a combination oral therapy approved to treat heart failure — rapidly reduces pulmonary blood pressure in people with pulmonary hypertension (PH) associated with heart failure with preserved ejection ... Read more

June 3, 2022June 3, 2022

High Rate of Hospitalization, Mortality With COVID-19: Study

COVID-19 News, Pulmonary Hypertension News

People with pulmonary hypertension (PH) who were diagnosed with COVID-19 had a high rate of hospitalization and in-hospital mortality, a French study concluded. Risk factors for adverse outcomes included being ... Read more

June 1, 2022June 1, 2022

Lowering Pulmonary Blood Pressure Linked to Better Survival in Study

Pulmonary Hypertension News

A mean pulmonary artery pressure (mPAP) — blood pressure in the lungs — of less than 40 mmHg (millimeters of mercury) significantly increases the survival rate of patients with different ... Read more

May 27, 2022May 27, 2022

Way of Diagnosing PH in Common Heart Test Gets FDA Support

Pulmonary Hypertension News

Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). Developed through a collaboration of ... Read more

May 25, 2022May 25, 2022

Tyvaso DPI Approved by the FDA for PAH and PH-ILD

Pulmonary Hypertension News

The U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI, a dry powder, inhaled formulation of treprostinil, to improve exercise ability in people with pulmonary arterial hypertension (PAH) or ... Read more

May 23, 2022May 23, 2022

Sacubitril/Valsartan Combo Found in Analysis to Improve Heart Function

Pulmonary Hypertension News

Sacubitril/valsartan, a fixed-dose combination oral therapy approved for heart failure, was found to improve right heart function and lower pulmonary blood pressure, according to a new pooled analysis of multiple ... Read more

May 20, 2022May 20, 2022

PAH Mortality Risk ‘Unacceptably High’ in the Modern Era, Study Finds

Pulmonary Hypertension News

Even with modern advances in treatments, many people in the U.S. with pulmonary arterial hypertension (PAH) are at an “unacceptably high” risk of mortality, a new study shows. The study, ... Read more

May 18, 2022May 18, 2022

Inhaled Imatinib, AV-101, Tolerated Well at All Doses in Phase 1 Trial

Pulmonary Hypertension News

Aerovate Therapeutics‘ AV-101, an inhaled formulation of imatinib for treating pulmonary arterial hypertension (PAH), was well tolerated in healthy adult volunteers enrolled in a Phase 1 trial. Study data also ... Read more

May 16, 2022May 16, 2022

Switching from Tracleer to Opsumit May Benefit Some PAH Patients

Pulmonary Hypertension News

Switching from Tracleer (bosentan) to Opsumit (macitentan) improved physical abilities with fewer side effects in some adults with pulmonary arterial hypertension (PAH), a study showed. Replacing Tracleer with Opsumit may ... Read more